Sotio Expands ADC Pipeline, Boehringer Inks GPCR Discovery Deal

Sotio Biotech, a Czech pharmaceutical company, is deepening its commitment to bispecific antibody-drug conjugates (ADCs) by exercising its option to utilize Synaffix's technology for two new candidates. Simultaneously, German pharmaceutical giant Boehringer Ingelheim has entered into a partnership with Salipro Biotech to advance GPCR-targeted drug discovery. These developments mark significant progress in the evolving landscape of targeted cancer therapies and drug discovery technologies.

Sotio's Strategic Expansion in Bispecific ADCs

Sotio Biotech has announced the addition of two new bispecific ADC candidates, SOT112 and SOT113, to its pipeline. This move comes as part of the company's ongoing strategy to build a robust ADC portfolio through collaborations with various technology providers.

The newly disclosed candidates leverage Synaffix's ADC technologies, including specialized linker-payloads. SOT112 is being developed for multiple major cancer indications, while SOT113 shows promise in precision targeting of prostate cancer. Both candidates are currently in the lead nomination stage.

Radek Spisek, CEO of Sotio, commented on the development: "The addition of SOT112 and SOT113 to our pipeline represents a significant milestone in our ADC development strategy. These candidates, built on highly attractive target pairs, have the potential to address significant unmet needs in cancer treatment."

Boehringer Ingelheim's GPCR Discovery Partnership

In a separate but equally noteworthy development, Boehringer Ingelheim has partnered with Salipro Biotech to enhance its drug discovery efforts targeting G protein-coupled receptors (GPCRs), ion channels, and other integral membrane proteins.

The collaboration aims to leverage Salipro's proprietary technology for stabilizing membrane proteins in their native forms. This approach is crucial for drug discovery efforts focused on challenging targets such as GPCRs, which are notoriously difficult to work with due to their instability when removed from cellular membranes.

Boehringer Ingelheim plans to apply this technology to its research in mental health and cardio-renal-metabolic diseases, potentially opening new avenues for drug development in these areas.

Dr. Mathias Wienand, Head of Global Research at Boehringer Ingelheim, stated, "This partnership with Salipro Biotech aligns perfectly with our commitment to innovation in drug discovery. By stabilizing these complex membrane proteins, we hope to unlock new possibilities in targeting previously challenging disease pathways."